BEVERLY HILLS, CA – GLP-1 medications like semaglutide and tirzepatide have reshaped the conversation around weight management, but a growing number of patients are now exploring a different approach: microdosing. Rather than taking standard doses for significant weight loss, some individuals are turning to smaller, off-label amounts of these medications for targeted benefits like reduced inflammation, weight maintenance, and even longevity support. In a recent feature for NewBeauty, Beverly Hills facial plastic surgeon Dr. Babak Azizzadeh weighed in on this emerging trend and its potential effects on facial aesthetics.
Dr. Azizzadeh suggests smaller GLP-1 doses might lower inflammation, similar to standard doses, noting this practice often emerges in wellness centers like Los Angeles first. Though some clinicians accept reduced long-term dosing, microdosing lacks FDA approval and requires qualified medical oversight.
Dr. Azizzadeh warned that microdosing at a normal weight risks unexpected facial hollowness from even minor weight loss. He now prefers fat transfer over injectable fillers to restore volume, reflecting a broader aesthetic shift toward natural, lasting results.
As GLP-1 medications continue to expand beyond traditional weight loss, the link between these drugs and facial aging is becoming harder to ignore. Patients considering microdosing or currently using GLP-1 medications should consult with a qualified facial plastic surgeon to anticipate and address changes in facial volume.
Read the full article on NewBeauty:
Is Microdosing GLP-1s the Next Big Health Hack?
Related resources: